| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 06/01/2005 | EP1453820B1 Substituted 6h-dibenzo[c,h]chromenes as estrogenic agents |
| 06/01/2005 | EP1404330B1 Substituted 8-arylquinoline pde4 inhibitors |
| 06/01/2005 | EP1268465B1 Triarylimidazole derivatives as cytokine inhibitors |
| 06/01/2005 | EP1233951B1 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| 06/01/2005 | EP1188754B1 Substituted pyrazole compounds |
| 06/01/2005 | EP1178977B1 Ion channel modulating agents |
| 06/01/2005 | EP1062210B1 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors |
| 06/01/2005 | CN1622995A Receptor nucleic acids and polypeptides |
| 06/01/2005 | CN1622957A IFNAR2 mutants, their production and use |
| 06/01/2005 | CN1622946A Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| 06/01/2005 | CN1622941A Glutaminyl based DPIV inhibitors |
| 06/01/2005 | CN1622830A Peptide-based compounds |
| 06/01/2005 | CN1622826A Stimulation of bone growth and cartilage formation with thrombing peptide derivatives |
| 06/01/2005 | CN1622812A Prophylactic and therapeutic treatment of infectious and other diseases with immune effect compound |
| 06/01/2005 | CN1621526A Recombinant adeno-associated virus for prevention and cure of I-type diabetes and use thereof |
| 06/01/2005 | CN1621065A Chinese traditional medicine for treating hyperosteogeny |
| 06/01/2005 | CN1621063A Medicinal tablet for resisting hyperosteogeny |
| 06/01/2005 | CN1621051A Hyperosteogeny plaster |
| 06/01/2005 | CN1621044A Composition for preventing and treating arthritis, formulation containing said composition, its preparation process and usage |
| 06/01/2005 | CN1621023A Sheep catghut soak |
| 06/01/2005 | CN1203899C Compounds with chelation affinity and selectivity for first transition series elements, and their use in medical therapy |
| 06/01/2005 | CN1203887C Traditional Chinese medicine for treating arthralgia and preparation process thereof |
| 06/01/2005 | CN1203879C Medicine for treating rheumatoid and rheumatic diseases |
| 06/01/2005 | CN1203852C Valdecoxib compositions |
| 05/31/2005 | US6900344 Method of preparing alkylated salicylamides via a dicarboxylate intermediate |
| 05/31/2005 | US6900336 8-aza-11-deoxy prostaglandin analogues |
| 05/31/2005 | US6900318 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| 05/31/2005 | US6900243 Phenylheteroalkylamine derivatives |
| 05/31/2005 | US6900240 Enriched in at least two of the phytochemicals selected from the group consisting of isoflavones, lignans, saponins, catechins and phenolic acids. |
| 05/31/2005 | US6900232 For therapy of tumor metastasis, solid tumor growth (neoplasia), osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, osteopenia, angiogenesis, including tumor angiogenesis and lymphangiogenesis |
| 05/31/2005 | US6900230 Heterocyclo-alkylsulfonyl pyrazoles as anti-inflammatory/analgesic agents |
| 05/31/2005 | US6900226 Quinoline and quinazoline derivatives; prophylaxis or treatment of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity. |
| 05/31/2005 | US6900216 Psychological disorders; antidepressants; brain diosrders; anticonvulsants |
| 05/31/2005 | US6900214 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| 05/31/2005 | US6900211 CCR5 antagonists useful for treating aids |
| 05/31/2005 | US6900201 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/31/2005 | US6900043 Phosphatases which activate map kinase pathways |
| 05/31/2005 | US6899888 Suppressing bone disordes such as decalcification or fractures in humans having prostate gland cancers by administering antiestrogen selected from triphenylethylene or toremifene; hormone inhibitors |
| 05/31/2005 | US6899873 Porous, biodegradable polymer; tissue culture |
| 05/31/2005 | CA2324343C C11 oxymyl and hydroxylamino prostaglandins useful as medicaments |
| 05/26/2005 | WO2005047282A1 Antiresorptive mutual salt of raloxifene and bisphosphonic acid |
| 05/26/2005 | WO2005046569A2 Pharmaceutical compositions for the treatment of sars |
| 05/26/2005 | WO2005028438A9 Novel piperidine derivative |
| 05/26/2005 | US20050113577 Such as hydrochloride salt 3-[5-(4-methanesulfonyl-piperazin-1-yl-methyl)-1H-indol-2-yl]-1H-quinolin-2-one; signal transduction; for treatment of angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, and inflammatory diseases |
| 05/26/2005 | US20050113451 7-acetamidinyl derivatives |
| 05/26/2005 | US20050113430 2-[o-(aminoalkoxy)phenyl])-3-acylbenzothiazolines, e.g., 3-Acetyl-6-chloro-2-[2-(3-(N-(2-hydroxyethyl)-N-isopropylamino)-propoxy)-5-methoxyphenyl]benzothiazoline; treating pruritus or pain, particularly that caused by a rheumatic disease |
| 05/26/2005 | US20050113416 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 05/26/2005 | US20050113414 1-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(3,4-dichlorophenyl)-urea; potent and selective modulators of CXCR3, a chemokine receptor; antagonists; treatment of conditions involving inappropriate T-cell trafficking; antiinflammatory, -arthritic agents, autoimmune diseases; antiallergens |
| 05/26/2005 | US20050113377 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase, 2 (COX-2) inhibitors |
| 05/26/2005 | US20050113370 Therapeutic substituted indazole derivatives |
| 05/26/2005 | US20050113368 eg (+-) Ethyl 3-[4-{3-(3,4-dihydro-2H-benzo[b][1,4]oxazin-4-yl)propylamino}phenyl]-2-ethoxypropanoate; antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic |
| 05/26/2005 | US20050113332 Compositions and methods for treating an arthritic condition |
| 05/26/2005 | US20050113303 Method for treating metabolic bone disease such as osteomalacia and osteoporosis in a patient by administering a compound that modulates phosphate regulating endopeptidase homolog (PEX) expression and/or PEX enzymatic activity |
| 05/26/2005 | US20050113301 Administering calcitonin and dehydroepiandrosterone (DHEA) to patient being treated for systemic lupus erythematosus where the immunosuppressant tends to reduce bone mineral density(BMD); osteoporosis |
| 05/26/2005 | US20050113299 Protein a compositions and methods of use |
| 05/26/2005 | US20050113291 Use of a substance which binds to and initiates signaling of the human SARP-1 receptor or a substance which stimulates release or potentiates the activity of endogenous SARP-1 for the manufacture of a medicament for the treatment and/or prevention of scleroderma, in particular of systemic sclerosis |
| 05/26/2005 | US20050113284 Drug for regenerating tissue and vessel and method therefor |
| 05/26/2005 | US20050112725 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 05/26/2005 | US20050112692 Screening peptide library; incubation complexing |
| 05/26/2005 | US20050112574 Isolated nucleic acid; angiogenesis inhibitor |
| 05/26/2005 | US20050112565 Proteases |
| 05/26/2005 | US20050112206 Mixture of drug, aminoacrylate polymer and acid |
| 05/26/2005 | US20050112202 tableting processes and equipment, and improved solid dosage forms for oral delivery of drugs that cause contact irritation or ulceration to the lining of the esophagus and stomach |
| 05/25/2005 | EP1533374A1 Novel peptides having camp producing activity |
| 05/25/2005 | EP1533294A1 Beta-alanine derivative and use thereof |
| 05/25/2005 | EP1532250A1 Fcyriia transgenic animal model for autoimmune disease |
| 05/25/2005 | EP1532242A2 Methods for preparing purified prostaglandin e synthase |
| 05/25/2005 | EP1532238A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 05/25/2005 | EP1532176A2 Cd200-receptor mediated modulation of bone development |
| 05/25/2005 | EP1532150A1 Novel purine derivatives, production and use thereof as medicaments |
| 05/25/2005 | EP1532148A1 Novel purine- or pyrrolol(2,3-d)pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity |
| 05/25/2005 | EP1532135A1 Nf-kb inhibitors |
| 05/25/2005 | EP1532134A1 Novel thiophene acyl hydrazino derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use |
| 05/25/2005 | EP1532133A1 Nf-:b inhibitors |
| 05/25/2005 | EP1532121A1 New use of pyrimidine - or triazine- 2-carbonitiles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitile derivatives |
| 05/25/2005 | EP1531904A1 Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| 05/25/2005 | EP1531855A2 Treatment of bone disorders with skeletal anabolic drugs |
| 05/25/2005 | EP1531847A2 Pharmaceutical formulation |
| 05/25/2005 | EP1531834A1 Antisense compounds, methods and compositions for treating ngal-related inflammatory disorders |
| 05/25/2005 | EP1531833A1 Antisense compounds, methods and compositions for treating mmp-12 related inflammatory disorders |
| 05/25/2005 | EP1531830A1 Method for reducing c-rective protein levels with non-antibacterial tetracycline formulations |
| 05/25/2005 | EP1531817A1 Glycinamide derivatives as raf-kinase inhibitors |
| 05/25/2005 | EP1531812A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis |
| 05/25/2005 | EP1531808A1 Peroxynitrite rearrangement catalysts used for the treatment or prophylaxis of diseases caused by peroxynitrite-mediated reactions |
| 05/25/2005 | EP1531807A1 Bazedoxifene treatment regimens |
| 05/25/2005 | EP1531716A2 Methods for using adamts-12, an integrin and metalloprotease with thrombospondin motifs |
| 05/25/2005 | EP1287137B1 REGULATION OF HUMAN $g(a)1A?ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR |
| 05/25/2005 | EP1286673B1 Ligands of integrin receptors |
| 05/25/2005 | EP1165081B1 Process for preparing tolperison-containing pharmaceutical preparations for oral administration |
| 05/25/2005 | EP1115434B1 Adhesive protein foam for surgical and/or therapeutic uses |
| 05/25/2005 | EP1039911B1 MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA 2 INHIBITORS |
| 05/25/2005 | DE10359336A1 Use of potassium channel openers in synergistic combination with sodium channel inhibiting/influencing active compounds for treating pains accompanied by increase in muscle tone |
| 05/25/2005 | DE10359335A1 Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen Combinations of potassium channel openers and sodium channel inhibitors and sodium channel influencing agents for the treatment of pain |
| 05/25/2005 | DE10297736T5 Arzneimittel zur Prävention und Behandlung von Knochenfrakturen und Osteoporose Products for the prevention and treatment of bone fractures and osteoporosis |
| 05/25/2005 | CN1620467A Secreted protein |
| 05/25/2005 | CN1620461A 2-amino-propanol derivatives |
| 05/25/2005 | CN1620459A 稠合双环嘧啶衍生物 Fused bicyclic pyrimidine derivative |
| 05/25/2005 | CN1620457A Tetracyclic heterocompounds as estrogen receptor modulators |
| 05/25/2005 | CN1620451A Benzhydryl derivatives |
| 05/25/2005 | CN1620435A 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders |